Smithfield Trust Co Sells 1,271 Shares of Bristol-Myers Squibb (NYSE:BMY)

Smithfield Trust Co cut its stake in shares of Bristol-Myers Squibb (NYSE:BMYFree Report) by 5.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,047 shares of the biopharmaceutical company’s stock after selling 1,271 shares during the period. Smithfield Trust Co’s holdings in Bristol-Myers Squibb were worth $1,077,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. increased its position in Bristol-Myers Squibb by 3.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 463,064 shares of the biopharmaceutical company’s stock worth $26,876,000 after buying an additional 13,562 shares during the last quarter. TIAA Trust National Association purchased a new stake in shares of Bristol-Myers Squibb during the 3rd quarter valued at approximately $8,023,000. Portside Wealth Group LLC boosted its holdings in Bristol-Myers Squibb by 1.9% in the 3rd quarter. Portside Wealth Group LLC now owns 15,210 shares of the biopharmaceutical company’s stock worth $883,000 after buying an additional 290 shares during the period. Northwest Bancshares Inc. grew its stake in Bristol-Myers Squibb by 22.7% in the 3rd quarter. Northwest Bancshares Inc. now owns 5,765 shares of the biopharmaceutical company’s stock valued at $335,000 after buying an additional 1,065 shares in the last quarter. Finally, Assetmark Inc. raised its holdings in Bristol-Myers Squibb by 10.1% during the 3rd quarter. Assetmark Inc. now owns 140,355 shares of the biopharmaceutical company’s stock valued at $8,146,000 after acquiring an additional 12,846 shares during the period. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Stock Performance

Shares of BMY traded up $0.20 during mid-day trading on Friday, reaching $44.94. The company had a trading volume of 8,616,072 shares, compared to its average volume of 14,307,914. Bristol-Myers Squibb has a 52 week low of $43.33 and a 52 week high of $69.10. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99 and a current ratio of 1.11. The firm has a 50-day moving average price of $49.84 and a 200 day moving average price of $50.39.

Bristol-Myers Squibb (NYSE:BMYGet Free Report) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.53) by $0.13. The company had revenue of $11.87 billion for the quarter, compared to analysts’ expectations of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. Bristol-Myers Squibb’s revenue was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.05 EPS. Equities research analysts forecast that Bristol-Myers Squibb will post 0.59 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, May 1st. Investors of record on Friday, April 5th were issued a $0.60 dividend. The ex-dividend date of this dividend was Thursday, April 4th. This represents a $2.40 annualized dividend and a yield of 5.34%. Bristol-Myers Squibb’s payout ratio is -77.42%.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on BMY shares. William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. Barclays decreased their price target on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a report on Friday, April 26th. StockNews.com lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Monday, April 15th. Societe Generale cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. Finally, BMO Capital Markets lowered their price target on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a report on Friday, April 26th. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $60.00.

Read Our Latest Stock Analysis on BMY

About Bristol-Myers Squibb

(Free Report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Read More

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMYFree Report).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.